Health Economics & Outcomes Research (HEOR)

What AI Finds in Clinical Notes About Myasthenia Gravis That Claims Data Misses

Speed Matters: Why RWE Acceleration Starts Upstream with Reusable Data

AI in HEOR: Three Ways Artificial Intelligence Is Accelerating Evidence Generation

HealthEconomics.com 2026 Pulse Check – March

When the Evidence Fails the Drug: Is the Role of Study Design Being Overlooked During Discovery?

Navigating Shifts in Pharmaceutical Policy: Impacts and Future Outlook

ウェビナー

Getting COA strategy right from the start: Early endpoint decisions that strengthen evidence and reduce risk

ウェビナー

Filling the Gap: Integrating Patient-Generated Data into Real-World Evidence

ウェビナー

Closing Gaps in Care: Health Equity and the Inflation Reduction Act - A Cutting Edge Conversation

ウェビナー

Network meta-analysis and its role in evidence-based decision-making

ウェビナー

Addressing Orphan and Rare Diseases - A Cutting Edge Conversation

ウェビナー

Joint Clinical Assessment 2025: Pioneering Pathways for Oncology, Advanced Therapies & Rare Diseases

ウェビナー

RWE reality check: Routine patient health records and regulatory requirements

ウェビナー

"S" Stands for Systematic: Demystifying the Systematic Literature Review

ウェビナー

Survival Analysis for Immature Data: A Review of Techniques and Lessons Learned

ウェビナー

Market Access - Transforming BioTech Commercial Decisions?

ウェビナー

The Scientific and Operational Elegance of Study Replication with Real-World EHR Data: A Vitiligo and Alopecia Example

ウェビナー

Insights from the 2024 Salary Survey Report by HealthEconomics.com

ウェビナー

Patient Voices Matter: Transforming Industry-Sponsored Real-World Evidence with Patient-Centric Approaches

ウェビナー

Integrated Evidence Generation Planning: Driving Successful Reimbursement and Life Cycle Management

ウェビナー

Strategies to Optimize Commercialization of Oncology Treatments for Younger Adults

ウェビナー

Navigating the Clinical Outcomes Maze: An Overview of Clinical Outcomes Assessments and Why Training Matters

ウェビナー

EU HTA Joint Clinical Assessments: Navigating Potential Challenges Ahead of 2025

ウェビナー

Bridging the Gap: Strategies for Patient-Centered Real-World Evidence in Rare Diseases

ウェビナー

Pharma can target ultra-rare conditions ‚Äî the next step is financing them

ウェビナー

Transforming Healthcare Using Big Data and Remote Monitoring

ウェビナー

Partnering with Disease Registries: The Value and Impact for Real-World Evidence Generation

ウェビナー

Minimizing the Impact of Cross-Cultural Differences in COA Translations

ウェビナー

Synthesise RWE and AI. Transform patient-driven healthcare

ウェビナー

Endpoints at #DIA23

ウェビナー

Certified Corporate Wellness Specialist(CCWS): Is It For Me?

ウェビナー

L7|LIVE SF - Tuesday, June 13th, 2023

ウェビナー

Connected communities: Advancing population health through data and emerging technology

ウェビナー

The reimagined hospital: How health systems are keeping up with new tech

ウェビナー

Clinical Trial Innovation: How Healthcare Technology is Evolving

ウェビナー

Driving value from healthcare data: How integrated cloud-based data is foundational to drive enterprise change

ウェビナー

Advancing identity data management for digital engagement: How leading organizations are doing it

ウェビナー

How Digital Health Can Empower Cancer Patients

ウェビナー

Keeping up with demands for healthcare outside of the hospital: Critical ways tech supports the distributed care model

ウェビナー

Closing the gaps of getting data to make decisions

ウェビナー

Medicare Part D: Price Negotiation Panel Discussion

ウェビナー

From Challenges to Opportunities: Navigating the EU MDR as a Medical Device Manufacturer

ウェビナー

What Every Researcher Needs to Know About Using Medicare Data for Real World Evidence

ウェビナー

Finding Value in Linking Real-World Data with Social Determinants of Health

ウェビナー

Unlock the Power of Data Review & Collaboration: Maximizing Trial Success

ウェビナー

Ushering in the new era of payvider integration

ウェビナー

How to Supercharge Real World Evidence Generation in Phase IV Trials

ウェビナー

Partnering with NHS in a crisis: The role for industry

ウェビナー

HTA Implementation in the MEA Region - an Overview from WHO and Country Updates

ウェビナー

Improving Treatment Access & Outcomes by Integrating Social Determinants of Health Data with Real-World Evidence

ウェビナー

Webcast: Taking the Complexity Out of Leveraging Health Plan Price Transparency Data

ウェビナー

FDA Patient-Focused Drug Development (PFDD) Guidance

ウェビナー

Creating Digital Biomarkers with Real-World and Existing Data by Xtalks

ウェビナー

Beyond the payment variance report: How to resolve common, costly underpayment issues

ウェビナー

Webcast: Strategies to Simplify Insurance Discovery

ウェビナー

Different HTA Perspectives on Reliably Estimating Treatment Effects

ウェビナー

Health Economic and Outcome Research (HEOR) for Medical Technologies for the US Healthcare Systems

ウェビナー

Measuring the intangible- what is the true value of a "patient centric" initiative

ウェビナー

Looking Beyond Survival Data: Understanding the Value of Non-OS Endpoints in Oncology Reimbursement Decision-Making

ウェビナー

Streamlining Health Technology Assessments by Automating Literature Reviews

ウェビナー

Champion a seamless end-to-end insight generation process

ウェビナー

Evidence Matters 2022

ウェビナー

Achieving Consensus When Everyone is an Expert, but No One Agrees

ウェビナー

Accelerating the Generation of Payer Insights and Evidence Across the Product Lifecycle to Achieve Optimal Access

ウェビナー

The Biotech landscape: Market trends, priorities, predictions, and pathways to FDA approval

ウェビナー

Making HEOR More Accessible to Patients

ウェビナー

Fit for Local Context? Establishing or Improving Deliberative Processes for HTA

ウェビナー

An Introduction to Infectious Disease Modeling

ウェビナー

When the Barrier to a Breakthrough Drug is You Can't Make It - September 28th

ウェビナー

US Drug Pricing Reform: Potential impact on Pharma HEOR Evidence Generation - September 8th

ウェビナー

Cell & Gene Day 2022 | Virtual Event | August 24th

ウェビナー

Confronting care inequities in hospital medicine - August 18th, 2022

ウェビナー

Biology's modern LIMS for labs of the future - August 17 | 12:00 pm - 1:00 pm EDT

ウェビナー

Pain R&D: Plenty of pain to go around, but who's making gains?

ウェビナー

Evidence Synthesis for Sparse Evidence Base, Heterogeneous Studies, and Disconnected Networks

ウェビナー

AI and Machine Learning Technologies: The New Normal of the Pharmaceutical Industry - July 27th

ウェビナー

Optimize Your Value Story Through Integrated Evidence Generation - From Bench to Patient

ウェビナー

Understanding Health Care Decision Maker Preferences for Optimized Engagement

ウェビナー

Data Integrity in Decentralized Clinical Trials (DCTs)

ウェビナー

How Cerner Enviza Uses Clinical Data to Drive RWE Decisions

ウェビナー

Optimizing Real-World Evidence for Maternal and Neonatal Outcomes

ウェビナー

How Literature Review Automation and Efficient Processes Streamline RWE HEOR Studies

ウェビナー

Digital Transformation to Support Operational, Therapeutic and Clinical Decision Making

ウェビナー

Respiration in Anesthetized Mice: Evidence-Based Recommendations for Improved Monitoring & Supportive Care

ウェビナー

Patient-Centric RWE Research & Remote Monitored Care: Learnings from a support program leveraging telehealth & connected devices

ウェビナー

Value-Based Agreements - Are We Going to See More or Less of Them?

ウェビナー

Selecting Rapid Review Methods for Health Technology Assessment

ウェビナー

Can Literature Review Automation Improve Healthcare Cost-Effectiveness Analysis and Budget Impact Modeling Outcomes?

ウェビナー

Cutting Edge Conversations: Value, Access and Evidence - Biotech Market Access

ウェビナー

Using External Control Arm Studies in HTA Submissions: An Alternative, When RCTs are not Feasible

ウェビナー

Predicting Payer Uptake with Precision

ウェビナー

Informational Webinar & Alumni Panel: Online MS Degree, Pharm Outcomes & Policy

ウェビナー

It's Not FAIR! Improving Data Publishing Practices in Research-Interoperability

ウェビナー

Exploring Best Practices and Innovation in New Registry Handbook: Part 2 - Understanding Quality

ウェビナー

Rise of the Robots 2.0: Real Talk About Artificial Intelligence In Systematic Reviews

ポッドキャスト

From Data Access to Evidence Usability: Connecting Payer Policy, Real-World Data, and Clinical Context to Close the Evidence Gap

ポッドキャスト

Integrated Evidence Delivery: Why HEOR belongs at the heart of the Modern CRO

ポッドキャスト

INsights & OUTcomes with Dalfoni Banerjee

ポッドキャスト

tHEORetically Speaking: Rethinking Decentralization in Direct-to-Patient Studies

ポッドキャスト

INsights & OUTcomes with Renée Arnold

ポッドキャスト

Meeting the Resource Challenge - Why Biotechs Need a Different Kind of Partner

ポッドキャスト

INsights & OUTcomes with Matt McLoughlin

ポッドキャスト

INsights & OUTcomes with Catherine Bacon

ポッドキャスト

INsights & OUTcomes with Vernon Schabert

ポッドキャスト

INsights & OUTcomes with Rosa Willock

ポッドキャスト

INsights & OUTcomes with Chris O'Neill

ポッドキャスト

Between Two Scientists: Care During Pregnancy - How RWD Can Help Balance the Needs of Mom and Baby

ポッドキャスト

How AI-Powered Phenotyping Enhances the Patient Journey for Life Science Applications

ポッドキャスト

Podcast Q&A: Clinical Outcomes Assessments and Training

ポッドキャスト

Podcast Q&A: Patient-Centered Real-World Evidence in Rare Diseases

ポッドキャスト

Podcast Q&A: Real-World Evidence Generation with Disease Registries

ポッドキャスト

Podcast Q&A: Clinical Outcome Assessment (COA) Translations

ポッドキャスト

#ExpertAnswers: Christopher Perry and Homira Osman on Integrating Patients, Clinical, and Advocacy Partners with Preclinical Research Labs

ポッドキャスト

Total System Value - A DYNAMIC APPROACH TO VALUE DEMONSTRATION

ポッドキャスト

How AI Can Help Dermatology: Diagnosis, Treatment, Risk, and R&D

ポッドキャスト

Industry Insights with Sino Biological: Cytokines - Catalysts of the Regenerative Revolution

ポッドキャスト

Podcast Q&A: The Benefits of Linking SDOH with Other Real-World Data

ポッドキャスト

Podcast Q&A: Literature Reviews and Global Value Dossiers

ポッドキャスト

Podcast Q&A: HEOR for Medical Technologies for the US Healthcare System

ポッドキャスト

Podcast Q&A: Improving Health Literacy

ポッドキャスト

Getting Real About Real-World Data

デモを見る

現代のライフサイエンスを支えるデジタル基盤

プロバイダー、ワークフロー、承認、コンプライアンス、データ、支出を一元管理できるインテリジェントなプラットフォームをご紹介します。複雑なプロジェクトをより迅速に、高い可視性と管理体制のもとで推進することが可能です。